Antiviral nasal spray is being tested in Russia

Russia has begun testing a nasal spray against coronavirus. Despite the fact that the third dose of the vaccine has already begun to be administered in many countries, as well as in Greece, to people aged 50 and over.

The new version of the Sputnik-V vaccine, in the form of a nasal spray, will be tested in adults, Russian media reported. Russia is struggling to increase vaccination coverage of its citizens.

During the tests, which will be carried out in a clinic in St. Petersburg, volunteers will receive two doses of a nasal spray, Reuters reports, citing a government document.

In June, Russian authorities announced that a nasal spray vaccine had been successfully tested in children between the ages of 8 and 12 and is scheduled to be released in September, which has not yet happened.

The initial version of Sputnik V was the subject of a diplomatic scandal between Russia and the EU: the European Medicines Agency accuses Russia of not providing the required information, and Moscow accuses the EU of delaying approval for political reasons.

Merck, Sharp & Dohme (MSD) has announced that it will begin production of an anti-coronavirus drug by the end of 2021 that will have the active ingredient molnupiravir (μολνουπιραβίρη).

Today, the drug is an oral antiviral drug used to treat pneumonia and mild symptoms of coronavirus in adults, preventing the risk of serious illness or hospitalization. In terms of effectiveness, the drug reduced the risk of hospitalization or death by about 50%.

The production of this promising drug is awaiting the results of a clinical trial and its possible licensing by international regulatory bodies. Back on Tuesday, MSD, in partnership with Ridgeback Biotherapeutics, filed an emergency license application with the US Food and Drug Administration (FDA).

Source link

High-quality journalistic work cannot be free, otherwise it becomes dependent on the authorities or the oligarchs.
Our site is solely funded by advertising money.
Please disable your ad blocker to continue reading the news.
Best regards, editors